Integrating Spatial Transcriptomics and Proteomics:
Unlocking More from Every Tissue Section
About this webinar
Biological processes are shaped by changes across multiple molecular layers, including RNA and proteins, with no single layer telling the whole story. Integrating complementary modalities can provide a more complete view of health and disease, revealing cellular relationships and biological mechanisms that may be missed when analyzing individual data layers alone.
Join us for a multi-speaker webinar exploring how spatial proteomics can be integrated with spatial transcriptomics on the same tissue section to maximize biological insights from valuable tissue samples.
Phil Cheng, PhD, Geneva University Hospitals and University of Geneva, will share a workflow combining a 93-plex spatial proteomics antibody panel on the Akoya PhenoCycler-Fusion platform with Xenium spatial transcriptomics on the same tumor tissue section, highlighting practical considerations, image coregistration, and opportunities for deeper tissue characterization.
Sarp Uzun, MD, PhD, University Hospital Basel, will present his work on checkpoint inhibitor-induced liver injury (ChILI), using single-cell spatial proteomics, spatial transcriptomics, and bulk T-cell receptor sequencing to identify expanded cytotoxic CD8+ T-cell clones shared between liver and tumor and their interactions with macrophages.
Register to learn more about how to integrate spatial protein and RNA information and how it can reveal cellular interactions, disease mechanisms, and functional biology that may not be apparent from either modality alone. Attendees will gain practical insights into multimodal spatial workflows and learn how to unlock more information from every tissue section.
Who should attend
This webinar will appeal to:
- Clinical Development leaders
- Translational Medicine Scientists
- Biomarker Strategy teams
- Clinical Operations professionals
- Precision Medicine and Companion Diagnostic teams
- Medical Directors
- Clinical Laboratory Scientists
- Neuroscience Drug Development teams
- Oncology Translational Research teams
- Pharmaceutical and Biotechnology Program leaders
- CRO Scientific leadership
- Clinical Biomarker Directors
What you will learn
Attendees will gain insight into:
- How spatial proteomics and transcriptomics can be integrated on the same tissue section
- Key considerations for designing a multimodal spatial workflow
- How protein and RNA measurements can complement one another to deepen biological interpretation
Featured Speakers
Phil Cheng, PhD
Phil completed his PhD in Cancer Biology at the University of Zurich and continued with postdoctoral studies in Cancer Genomics. He is currently a Bioinformatician leading the Spatial Omics Lab of Prof. Olivier Michielin at the University of Geneva and Geneva University Hospitals, investigating spatial transcriptomic and proteomic biomarkers for cancer immunotherapy response.
For the past year, the team has been testing protocols to obtain the optimal conditions for Akoya PhenoCycler-Fusion and 10x Xenium on the same slide and co-registration workflows for multi modal analysis.
Sarp Uzun, MD, PhD
Sarp was born in Adana, Turkey. He graduated from Hacettepe University Faculty of Medicine in Ankara, Turkey, in 2020. In 2016, he enrolled in the MD-PhD program at the same university and received his PhD in 2021 from the Tumor Biology and Immunology PhD program.
In August 2021, Sarp joined the laboratory of Prof. Matthias Matter at the Institute for Medical Genetics and Pathology, University Hospital Basel, Switzerland, as a postdoctoral fellow. His research focuses on spatial characterization of adverse events caused by immune-checkpoint inhibitors, with a particular emphasis on the liver and gastrointestinal system.
Matthias Koenning, PhD
Matthias Koenning, PhD, is a Senior Field Applications Scientist at Quanterix Spatial, where he partners with researchers to advance discovery and translational science through multiplexed immunohistochemistry and spatial biology technologies. He earned his Ph.D. in Neuroscience from the University of Melbourne where his research focused on mechanisms of critical importance in brain development and Multiple Sclerosis related. He subsequently conducted research at Baylor College of Medicine at the intersection of neuroscience and precision environmental health. In his current role, he provides scientific guidance, technical expertise, and application support to help academic and biotechnological teams to translate complex biological questions into actionable data.
Partner for this event
Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.